Overview

GIOTRIF rPMS in Korean Patients With NSCLC

Status:
Completed

Trial end date:
2019-12-31

Target enrollment:

Participant gender:

Summary

To monitor the safety profile and efficacy of GIOTRIF® (afatinib dimaleate, q.d) in Korean patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)

Details

Lead Sponsor:

Boehringer Ingelheim